Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Viatris Inc.
Viatris Inc. News
Viatris Inc. Quantitative Score
About Viatris Inc.
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Viatris Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Viatris Inc. Financials
Table Compare
Compare VTRS metrics with: | |||
|---|---|---|---|
Earnings & Growth | VTRS | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | VTRS | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | VTRS | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | VTRS | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Viatris Inc. Income
Viatris Inc. Balance Sheet
Viatris Inc. Cash Flow
Viatris Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Viatris Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 0.4800 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2025-06-16 | 0.12 | Quarterly |
| 2025-03-18 | 0.12 | Quarterly |
| 2024-12-13 | 0.12 | Quarterly |
| 2024-09-13 | 0.12 | Quarterly |
| 2024-06-14 | 0.12 | Quarterly |
Historical Market Cap
Shares Outstanding
Viatris Inc. Executives
| Name | Role |
|---|---|
| Mr. Scott Andrew Smith Ph.D. | Chief Executive Officer & Director |
| Mr. Paul B. Campbell | Chief Accounting Officer, Senior Vice President & Corporate Controller |
| Ms. Theodora Mistras | Chief Financial Officer |
| Mr. Brian S. Roman | Chief Legal Officer |
| Dr. Corinne M. Le Goff M.B.A., Pharm.D. | Chief Commercial Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Scott Andrew Smith Ph.D. | Chief Executive Officer & Director | Male | 1962 | 4.96M |
| Mr. Paul B. Campbell | Chief Accounting Officer, Senior Vice President & Corporate Controller | Male | 1967 | 3.7M |
| Ms. Theodora Mistras | Chief Financial Officer | Female | 1982 | 2.74M |
| Mr. Brian S. Roman | Chief Legal Officer | Male | 1970 | 2.21M |
| Dr. Corinne M. Le Goff M.B.A., Pharm.D. | Chief Commercial Officer | 1965 | 1.79M |
Viatris Inc. Insider Trades
| Date | 12 May |
| Name | Smith Scott Andrew |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 60000 |
| Date | 12 May |
| Name | DAMELIO FRANK A |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 25112 |
| Date | 12 May |
| Name | SEVERINO MICHAEL |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 25112 |
| Date | 5 May |
| Name | DAMELIO FRANK A |
| Role | |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 5 May |
| Name | SEVERINO MICHAEL |
| Role | |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 12 May | Smith Scott Andrew | Chief Executive Officer | Acquired | P-Purchase | 60000 |
| 12 May | DAMELIO FRANK A | Director | Acquired | A-Award | 25112 |
| 12 May | SEVERINO MICHAEL | Director | Acquired | A-Award | 25112 |
| 5 May | DAMELIO FRANK A | Disposed | 0 | ||
| 5 May | SEVERINO MICHAEL | Disposed | 0 |